The operator of Kinney Drugs retail chain sued Takeda Pharmaceutical and Endo International over claims that the pharmaceutical manufacturers allegedly engaged in a pay-to-delay scheme to keep generic versions of Takeda’s anti-constipation drug Amitiza off the market.
Related: Takeda Wants 2nd Circuit To Toss Actos Antitrust Suit
KPH Healthcare Services’ antitrust lawsuit, filed Tuesday, August 3, in the US District Court for the District of Massachusetts, claimed that Japan-based Takeda and its US subsidiary, Takeda Pharmaceuticals USA, made “reverse payments” totaling between US$29 and US$280 million to an Endo subsidiary, Par Pharmaceuticals, to keep the generic from being introduced for over six years.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI